IGM Biosciences, Inc. - IGMS STOCK NEWS

IGM Biosciences (Nasdaq: IGMS) announced that CEO Fred Schwarzer will present at three investor conferences in November 2020. The conferences are: Stifel Virtual Healthcare Conference on November 16 at 3:20 p.m. ET, Jefferies Virtual London Healthcare Conference on November 17 at 2:20 p.m. ET, and Wolfe Research Healthcare Conference on November 18 at 12:55 p.m. ET. A live webcast will be available on the company’s website, with replays accessible for 90 days after the events.

IGM Biosciences (Nasdaq: IGMS) reported its Q3 2020 results, showing a net loss of $20.3 million, or $0.66 per share, up from a loss of $10.2 million in Q3 2019. Cash and investments decreased to $180.2 million from $236.6 million at year-end 2019. Key updates include initial Phase 1 data presentation for IGM-2323 at the ASH Annual Meeting in December and the initiation of the Phase 1 trial for IGM-8444. IGM also announced a collaboration with AbCellera for novel IgM antibody discovery. The company anticipates 2020 operating expenses of $80-$85 million.

IGM Biosciences (Nasdaq: IGMS) announced the upcoming presentation of initial clinical data for IGM-2323 at the ASH Annual Meeting on December 5, 2020. This bispecific IgM antibody aims to target CD20 on lymphoma cells and CD3 on T cells, presenting a novel approach to treating non-Hodgkin’s lymphoma. The Phase 1 trial has shown positive initial findings, with no dose-limiting toxicities reported among eight patients treated. Preliminary results indicated favorable safety profiles and T cell activation, suggesting potential advantages over traditional therapies.

IGM Biosciences has announced the dosing of the first patient in its Phase 1 clinical trial for IGM-8444, an IgM antibody targeting the DR5 protein in solid cancers and non-Hodgkin’s lymphoma. This multicenter trial will assess the pharmacokinetics, safety, and preliminary efficacy of IGM-8444 as a monotherapy and in combination with chemotherapy. Initial data is expected in 2021. The trial signifies a key milestone for IGM, marking the second program from its IgM antibody platform to enter clinical development.

IGM Biosciences (Nasdaq: IGMS) has announced the dosing of its first patient in a Phase 1 clinical trial for IGM-8444, an IgM antibody targeting DR5 in patients with solid tumors and non-Hodgkin’s lymphoma. The trial aims to assess pharmacokinetics, safety, and preliminary efficacy of IGM-8444, both alone and with chemotherapy. Initial data is expected in 2021. CEO Fred Schwarzer noted the trial's significance as part of IGM's strategy utilizing its proprietary IgM technology platform.

AbCellera and IGM Biosciences (Nasdaq: IGMS) have announced a strategic research collaboration aimed at developing novel IgM antibodies. This multi-year agreement involves AbCellera creating antibody panels for various therapeutic targets identified by IGM, which will then have the rights to develop and commercialize these antibodies. Financial details remain undisclosed. IGM aims to leverage this partnership to enhance its IgM and IgA technology platform, potentially addressing challenges in current therapies. Leadership from both companies expressed optimism regarding the collaboration's impact on therapeutic advancements.

IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will present at four investor conferences in September 2020. The conferences include:

• Baird 2020 Global Healthcare Conference on September 9 at 3:10 p.m. ET
• H.C. Wainwright 22^nd Annual Global Investment Conference on September 16 at 1:00 p.m. ET
• 2020 Cantor Global Virtual Healthcare Conference on September 17 at 4:40 p.m. ET
• Morgan Stanley 18th Annual Global Healthcare Conference on September 18 at 11:45 a.m. ET

Live webcasts will be available on the company's website with a 90-day archive.

IGM Biosciences (Nasdaq: IGMS) announced significant advancements, including FDA clearance for its IND application for IGM-8444, aimed at treating solid and hematologic malignancies. The Phase 1 trial will assess its efficacy alongside chemotherapy. Additionally, Kathy Miller, Ph.D., has been appointed Vice President of Antibody Discovery. Financially, IGM reported a Q2 2020 net loss of $18.8 million, an increase from the previous year, with cash reserves decreasing to $203.1 million. The company's guidance for 2020 remains unchanged, anticipating $75-$85 million in non-GAAP operating expenses.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm specializing in engineered IgM antibodies, announced that CEO Fred Schwarzer will present at the Jefferies 2020 Healthcare Conference. The presentation is scheduled for Thursday, June 4, at 10:00 a.m. ET, and will be conducted virtually. Interested participants can access a live webcast through the company’s website, with a replay available for 90 days post-event. IGM Biosciences focuses on advancing IgM antibody technologies, addressing existing manufacturing challenges since its inception in 2010.